ARWR Stock Overview
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Arrowhead Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$33.62 |
| 52 Week High | US$56.25 |
| 52 Week Low | US$26.81 |
| Beta | 1.01 |
| 1 Month Change | 11.03% |
| 3 Month Change | -3.20% |
| 1 Year Change | -38.49% |
| 3 Year Change | -20.73% |
| 5 Year Change | 514.63% |
| Change since IPO | -35.35% |
Recent News & Updates
Recent updates
A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jan 24
We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn
Oct 24Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities
Sep 12Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming
Aug 23Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease
Aug 17Arrowhead Pharmaceuticals: An RNAi Name To Know
Jul 28Arrowhead Pharmaceuticals names internal officer as new COO
Jul 20Arrowhead begins dosing in early-stage studies of 2 potential lung disease drugs
Jul 05Arrowhead Pharma: We Can Afford To Wait For More Proof
Jun 28Companies Like Arrowhead Pharmaceuticals (NASDAQ:ARWR) Can Afford To Invest In Growth
Jun 18Arrowhead Pharma: Know Pros' Calcs For Coming Stock Prices
Apr 14Are Investors Undervaluing Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) By 46%?
Feb 08Arrowhead: 2021 Was A Struggle Valuation Wise - Things May Get Worse In 2022
Jan 26Accumulate Arrowhead For Its RNAi Pipeline
Jan 17Johnson & Johnson's JNJ-3989 News Could Propel Arrowhead Stock To New All-Time Highs
Nov 03Are Investors Undervaluing Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) By 34%?
Oct 09The Partnership Effect: Arrowhead Forges Its Future
Aug 27Arrowhead Pharmaceuticals Dives On Safety Issues For ARO-ENaC, But Remains On Track In Other Indications
Jul 06Arrowhead and Horizon team up in potential $700M collaboration agreement
Jun 21Arrowhead: On Target With RNAi Innovation
Jun 14Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jun 14News Flash: 11 Analysts Think Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Earnings Are Under Threat
Feb 12
Here's What Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shareholder Ownership Structure Looks Like
Jan 20How Arrowhead Protects Its Intellectual Property
Dec 30Analyst Forecasts For Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Are Surging Higher
Nov 28Have Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Insiders Been Selling Their Stock?
Nov 27Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Nov 26Arrowhead Pharmaceuticals EPS of -$0.84
Nov 23Shareholder Returns
| ARWR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.7% | -0.5% | 1.6% |
| 1Y | -38.5% | 2.9% | -10.8% |
Return vs Industry: ARWR underperformed the US Biotechs industry which returned 2.9% over the past year.
Return vs Market: ARWR underperformed the US Market which returned -10.8% over the past year.
Price Volatility
| ARWR volatility | |
|---|---|
| ARWR Average Weekly Movement | 11.7% |
| Biotechs Industry Average Movement | 12.0% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ARWR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: ARWR's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 397 | Chris Anzalone | https://arrowheadpharma.com |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets.
Arrowhead Pharmaceuticals, Inc. Fundamentals Summary
| ARWR fundamental statistics | |
|---|---|
| Market Cap | US$3.64b |
| Earnings (TTM) | -US$154.52m |
| Revenue (TTM) | US$278.34m |
13.1x
P/S Ratio-23.6x
P/E RatioIs ARWR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARWR income statement (TTM) | |
|---|---|
| Revenue | US$278.34m |
| Cost of Revenue | US$0 |
| Gross Profit | US$278.34m |
| Other Expenses | US$432.85m |
| Earnings | -US$154.52m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.43 |
| Gross Margin | 100.00% |
| Net Profit Margin | -55.51% |
| Debt/Equity Ratio | 0% |
How did ARWR perform over the long term?
See historical performance and comparison